Premium
Plasma protein extravasation induced by mammalian tachykinins in rat skin: influence of anaesthetic agents and an acetylcholine antagonist
Author(s) -
Couture Réjean,
Kérouac René
Publication year - 1987
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1987.tb10281.x
Subject(s) - extravasation , neurokinin b , neurokinin a , atropine , substance p , chemistry , tachykinin receptor , endocrinology , medicine , muscarinic acetylcholine receptor , pharmacology , receptor , neuropeptide , biology , immunology
1 The effect of mammalian tachykinins on plasma protein extravasation was assessed in the rat dorsal skin. Substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) increased vascular permeability in a dose‐related manner with a threshold dose of about 0.07 pmol in sodium pentobarbitone‐anaesthetized animals. 2 Plasma protein extravasation induced by the tachykinins was 100–500 times less in magnitude in animals anaesthetized with urethane. 3 Plasma protein extravasation induced by SP (66 pmol) was significantly reduced (63%; P < 0.001) by atropine (a muscarinic inhibitor) while that induced by NKA or NKB was unaffected by the inhibitor suggesting that a cholinergic component might only be involved in the vascular permeability elicited by SP. 4 The rank order of potency for the tachykinins on plasma protein extravasation was: NKB > SP > NKA (in absence of atropine) and NKB > NKA > SP (in presence of atropine), suggesting that this vascular response is mediated by a SP‐E‐receptor type. 5 The amplitudes of the plasma protein extravasation induced by NKB and its hydrophilic analogue [Arg ° ]NKB were similar, indicating that the lipophilic features of the native peptide cannot account for its potent biological activity. 6 Plasma protein extravasation was enhanced by the SP analogue [ d ‐Pro 4 , Lys 6 , d ‐Trp 7,9,10 , Phe 11 ] SP (4–11), thus showing the limitation of such SP analogues (antagonists) for characterizing the tachykinin receptors involved in vascular permeability.